Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Bonny Johnson"'
Autor:
Weiqi Lin, Samiee Ahmad P, Gregory E. Hardee, Ching-Leou Teng, Michel J. N. Cormier, Angie Griffin, Peter E. Daddona, Bonny Johnson
Publikováno v:
Pharmaceutical Research. 18:1789-1793
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42c5a90929dde8fbd8d06e6ff2a65799
https://doi.org/10.1023/a:1013395102049
https://doi.org/10.1023/a:1013395102049
Publikováno v:
Journal of Controlled Release. 47:61-69
Transdermal powdered delivery (TPD) is a novel method for needle-free administration of drugs, vaccines, and other therapeutic compounds. In this study, the efficiency of the TPD method has been evaluated following delivery of radiolabeled inulin to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26909dbf5544964afebd19fead0a4ce5
https://doi.org/10.1016/s0168-3659(96)01616-1
https://doi.org/10.1016/s0168-3659(96)01616-1
Autor:
Mario Sznol, Ivana Gojo, Francis J. Giles, Lawrence E. Morris, Judith E. Karp, Bonny Johnson, Jennifer Low, Mya Sanda Thein, Jacqueline Greer
Publikováno v:
Leukemia research. 32(1)
Triapine is a potent ribonucleotide reductase (RR) inhibitor that depletes intracellular deoxyribonculeotide pools, especially dATP. We designed a Phase I trial of Triapine followed by the adenosine analog fludarabine in adults with refractory acute
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84d9b22b135b7168712157cfec2e94f7
https://pubmed.ncbi.nlm.nih.gov/17640728
https://pubmed.ncbi.nlm.nih.gov/17640728
Autor:
Ivana Gojo, Jacqueline Greer, Judith E. Karp, Mary F. Pochron, Michael L. Tidwell, Karen Seiter, Bonny Johnson, Naoko Takebe, Mario Sznol
Publikováno v:
Leukemia research. 31(9)
Triapine, a potent inhibitor of ribonucleotide reductase, has demonstrated anti-leukemia activity in pre-clinical models. We conducted a Phase I study of Triapine administered as a 2 h infusion for 5 days in 25 adults with advanced leukemias. We esta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b72054815c6ad75511bd528571ca376f
https://pubmed.ncbi.nlm.nih.gov/17416414
https://pubmed.ncbi.nlm.nih.gov/17416414
Autor:
Michel, Cormier, Bonny, Johnson, Mahmoud, Ameri, Kofi, Nyam, Luz, Libiran, Dee Dee, Zhang, Pete, Daddona
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society. 97(3)
Desmopressin is a synthetic peptide hormone chiefly used for treatment of enuresis in young children. It is available in injectable, intranasal, and oral formulations. While administration by injection is poorly suited for routine use in young childr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5b99c6aa2214fc252a9eb730083081fb
https://pubmed.ncbi.nlm.nih.gov/15212882
https://pubmed.ncbi.nlm.nih.gov/15212882
Autor:
James H. Doroshow, Mario Sznol, Yun Yen, Kim Margolin, Bonny Johnson, Daniel M. Sullivan, Caroline Clairmont, Mayer Fishman
Publikováno v:
Cancer chemotherapy and pharmacology. 54(4)
3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP), a new and potent inhibitor of ribonucleotide reductase (RR), increases the cellular uptake, DNA incorporation, and cytotoxicity of gemcitabine in tumor cell lines. A phase I trial was initiat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::341df18552792d7c12833222252c44d3
https://pubmed.ncbi.nlm.nih.gov/15148626
https://pubmed.ncbi.nlm.nih.gov/15148626
Autor:
Norbert Vey, Jonathan Kell, Scott R. Solomon, Robert K. Stuart, Gary J. Schiller, Daniel J. DeAngelo, Bonny Johnson, Susan O'Brien, Francis J. Giles, Arnaud Pigneux
Publikováno v:
Blood. 110:917-917
VNP40101M (Cloretazine®) is a novel sulfonylhydrazine alkylating agent which preferentially targets the O6 position of guanine resulting in DNA cross-links. Data from a previously reported phase II multi-center single agent study (CLI-033) in patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbf9cd633c98208c0c2871d27e428302
https://doi.org/10.1182/blood.v110.11.917.917
https://doi.org/10.1182/blood.v110.11.917.917
Autor:
Ann Cahill, Daniel J. DeAngelo, Norbert Vey, Robert K. Stuart, Bonny Johnson, Francis J. Giles, Wendy Stock, Susan O'Brien, Darinka Boskovic, Karen Seiter
Publikováno v:
Blood. 108:1970-1970
Background: AraC is considered to be the most effective single drug in the treatment of AML. For initial treatment of AML, araC is typically administered by intravenous continuous infusion for 5–7 days at doses of 100–200 mg/m2/day, usually in co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe393260370be4af78111e34131820c1
https://doi.org/10.1182/blood.v108.11.1970.1970
https://doi.org/10.1182/blood.v108.11.1970.1970
Autor:
Maureen Cooper, Norbert Vey, Judith E. Karp, Ghulam J. Mufti, Francis J. Giles, David A. Rizzieri, Verena Karsten, Bonny Johnson, Susan O'Brien
Publikováno v:
Blood. 106:2786-2786
Background: The majority of patients (pts) with AML and high risk MDS are ≥ 60 years of age at diagnosis (median age 70), and have a poor prognosis due to age-related risk factors and disease biology. Commonly accepted risk factors in this populati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2f028ab4fede60fa43fec3c6b5f14fa
https://doi.org/10.1182/blood.v106.11.2786.2786
https://doi.org/10.1182/blood.v106.11.2786.2786